Citations (45)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (11)
Rui Kang, Mengdi Song, Zhou Fang & Kehai Liu. (2023) Nano-composite hydrogels of Cu-Apa micelles for anti-vasculogenic mimicry. Journal of Drug Targeting 31:2, pages 166-178.
Read now
Read now
Zhangqiang Xiang, Xiangyu Deng, Wenfeng He, Qian Yang, Laichao Ni, Marzieh Dehghan Shasaltaneh, Mazaher Maghsoudloo, Gang Yang, Jingbo Wu, Saber Imani & Qinglian Wen. (2022) Treatment of malignant pleural effusion in non-small cell lung cancer with VEGF-directed therapy. Annals of Medicine 54:1, pages 1357-1371.
Read now
Read now
Wenxia Hu, Bin Li, Nan Geng, Xin He, Hui Ge, Ping Wang & Cuimin Ding. (2021) Association Between PDL1 Genetic Variation and Efficacy of Apatinib Monotherapy in Patients with Previously Treated Advanced NSCLC: A Real-World Retrospective Study. International Journal of General Medicine 14, pages 2703-2714.
Read now
Read now
Zi-Zheng Song, Li-Fen Zhao, Jing Zuo, Zhi-Song Fan, Long Wang & Yu-Dong Wang. (2020) Clinical Outcomes and Safety of Apatinib Mesylate in the Treatment of Advanced Non-Squamous Non-Small Cell Lung Cancer in Patients Who Progressed After Standard Therapy and Analysis of the KDR Gene Polymorphism. OncoTargets and Therapy 13, pages 603-613.
Read now
Read now
Liya Zhou, Jie Lin, Gang Wu, Jiawei Chen, Xiaopeng Huang & Shuai Zhang. (2020) Safety and Feasibility of Low-Dose Apatinib Combined with S-1 as the Second-Line Therapy or Beyond in Chinese Patients with Pulmonary and Hepatic Metastasis of Nasopharyngeal Carcinoma. Drug Design, Development and Therapy 14, pages 1257-1262.
Read now
Read now
Qin Shi, Yongning Lu, Songjiang Huang, Chen Zhou, Chongtu Yang, Jiacheng Liu, Jinqiang Ma & Bin Xiong. (2020) Apatinib-loaded CalliSpheres Beads for embolization in a rabbit VX2 liver tumor: characterization in vitro, pharmacokinetics and tumor response in vivo. Drug Delivery 27:1, pages 1301-1307.
Read now
Read now
Meng Su, Ya Gao, XuXue Ye, QingYu Zhou, LiHao Zhao, Xiaona Cai, Didi Chen, Huafang Su, Xiaohua Zhang & Congying Xie. (2019) Clinical Value Of Apatinib As A Salvage Treatment In Patients With Chemo-Refractory Advanced Cervical Cancer. OncoTargets and Therapy 12, pages 9707-9713.
Read now
Read now
Wenli Zuo & Lingdi Zhao. (2019) Recent advances and application of PD-1 blockade in sarcoma. OncoTargets and Therapy 12, pages 6887-6896.
Read now
Read now
Chao Chen, Shukui Qin, Zixiong Li, Xianwen Luo, Yu Zhang, Jue Zhang & Xiufeng Liu. (2019) A retrospective six-patient series of apatinib for the treatment of persistent or recurrent carcinoma of the cervix. OncoTargets and Therapy 12, pages 5805-5811.
Read now
Read now
Di Zhang, Jiaqi Huang, Yulan Sun & Qisen Guo. (2019) Long-term progression-free survival of apatinib monotherapy for relapsed ovarian cancer: a case report and literature review. OncoTargets and Therapy 12, pages 3635-3644.
Read now
Read now
Ying Zhang, Jia-Yun Zou, Zhe Wang & Ying Wang. (2019) Fruquintinib: a novel antivascular endothelial growth factor receptor tyrosine kinase inhibitor for the treatment of metastatic colorectal cancer. Cancer Management and Research 11, pages 7787-7803.
Read now
Read now
Articles from other publishers (34)
Rui Liu & Lijun Liu. (2023) Use of Apatinib as a Bait to Fish its Unexpected Kinase Targets from the Hepatocellular Carcinoma Druggable Kinome. Journal of Computational Biophysics and Chemistry 22:04, pages 439-451.
Crossref
Crossref
Xin‐Mei Yang, Pan‐Pan Ye, Xiao‐Lin Liu, Zi‐Xuan Guo, Min Kan, Qian Li, Lin‐Lin Song, Hong‐Ying Liu, Ke‐Guang Chen, Jin‐Yi Shi, Ye‐Hui Zhang, Ya Li, Fu‐Rong Zhao, John van den Anker, Yan Li & Wei Zhao. (2023) Population pharmacokinetics and pharmacogenetics of apatinib in adult cancer patients. British Journal of Clinical Pharmacology 89:6, pages 1862-1872.
Crossref
Crossref
Wei Fan, Jun Ding & Wei Zhong. (2023) Efficacy and Safety of Third-Line Apatinib plus Chemotherapy in Metastatic Triple-Negative Breast Cancer Patients: A Multicenter, Retrospective, Cohort Study. The Tohoku Journal of Experimental Medicine 260:1, pages 13-20.
Crossref
Crossref
Longbo Yu, Yuanyuan Wang, Yingxue He, Haiqing Zhong, Shushan Ge, Yi Zou, Yisheng Lai, Qiang Xu, Jian Gao, Wen Liu & Wenjie Guo. (2022) Combination of apatinib with apo-IDO1 inhibitor for the treatment of colorectal cancer. International Immunopharmacology 112, pages 109233.
Crossref
Crossref
Flávia Melo Cunha de Pinho Pessoa, Caio Bezerra Machado, Emerson Lucena da Silva, Laudreísa da Costa Pantoja, Rodrigo Monteiro Ribeiro, Maria Elisabete Amaral de Moraes, Manoel Odorico de Moraes Filho, Raquel Carvalho Montenegro, André Salim Khayat & Caroline Aquino Moreira-Nunes. (2022) Solid Tumors and Kinase Inhibition: Management and Therapy Efficacy Evolution. International Journal of Molecular Sciences 23:7, pages 3830.
Crossref
Crossref
YanWei Li, Feng He, Yu Zhang & ZhanYu Pan. (2022) Apatinib and Ginsenoside-Rb1 Synergetically Control the Growth of Hypopharyngeal Carcinoma Cells. Disease Markers 2022, pages 1-14.
Crossref
Crossref
Marianna Nalli, Michela Puxeddu, Giuseppe La Regina, Stefano Gianni & Romano Silvestri. (2021) Emerging Therapeutic Agents for Colorectal Cancer. Molecules 26:24, pages 7463.
Crossref
Crossref
Ning Zhong, Wei Zhuang, Qian Huang, Qiang Wang & Wenjian Jin. (2021) Apatinib inhibits the growth of small cell lung cancer via a mechanism mediated by VEGF, PI3K/Akt and Ki‐67/CD31. Journal of Cellular and Molecular Medicine 25:21, pages 10039-10048.
Crossref
Crossref
Zhichao Tian, Xiaohui Niu & Weitao Yao. (2021) Efficacy and Response Biomarkers of Apatinib in the Treatment of Malignancies in China: A Review. Frontiers in Oncology 11.
Crossref
Crossref
Tai-Lin Chen, Anilkumar S. Patel, Vicky Jain, Ramajayam Kuppusamy, Yi-Wen Lin, Ming-Hon Hou, Tsann-Long Su & Te-Chang Lee. (2021)
Discovery of Oral Anticancer 1,2-Bis(hydroxymethyl)benzo[
g
]pyrrolo[2,1-
a
]phthalazine Hybrids That Inhibit Angiogenesis and Induce DNA Cross-Links
. Journal of Medicinal Chemistry 64:17, pages 12469-12486.
Crossref
Crossref
Shenglong Li. (2021) Anlotinib: A Novel Targeted Drug for Bone and Soft Tissue Sarcoma. Frontiers in Oncology 11.
Crossref
Crossref
Csongor György Lengyel, Sadaqat Hussain, Dario Trapani, Khalid El Bairi, Sara Cecilia Altuna, Andreas Seeber, Andrew Odhiambo, Baker Shalal Habeeb & Fahmi Seid. (2021) The Emerging Role of Liquid Biopsy in Gastric Cancer. Journal of Clinical Medicine 10:10, pages 2108.
Crossref
Crossref
Liying Zhao, Yanmei Peng, Sixiao He, Ru Li, Ziqing Wang, Junhao Huang, Xuetao Lei, Guoxin Li & Qiang Ma. (2021) Apatinib induced ferroptosis by lipid peroxidation in gastric cancer. Gastric Cancer 24:3, pages 642-654.
Crossref
Crossref
Dongmei Chi, Baoqing Chen, Suping Guo, Kunhao Bai, Huali Ma, Yonghong Hu, Qiaoqiao Li & Yujia Zhu. (2021) Oral maintenance therapy using apatinib combined with S-1/capecitabine for esophageal squamous cell carcinoma with residual disease after definitive chemoradiotherapy. Aging 13:6, pages 8408-8420.
Crossref
Crossref
Yingchao Zhang, Xianzhao Deng, Zheng Ding, Jie Kang, Bo Wu, Bomin Guo & Youben Fan. (2021) Preoperative neoadjuvant targeted therapy with apatinib for inoperable differentiated thyroid cancer. Medicine 100:12, pages e25191.
Crossref
Crossref
Ana Nogués, Eunate Gallardo-Vara, Mª. Paz Zafra, Paloma Mate, Jose Luis Marijuan, Alfredo Alonso, Luisa Mª. Botella & Mª. Isabel Prieto. (2020) Endoglin (CD105) and VEGF as potential angiogenic and dissemination markers for colorectal cancer. World Journal of Surgical Oncology 18:1.
Crossref
Crossref
Bin Wei, Yuanyuan Wang, Jiawei Wang, Xiaomin Cai, Lingyan Xu, Jingjing Wu, Ying Wang, Wen Liu, Yanhong Gu, Wenjie Guo & Qiang Xu. (2020) Apatinib suppresses tumor progression and enhances cisplatin sensitivity in esophageal cancer via the Akt/β-catenin pathway. Cancer Cell International 20:1.
Crossref
Crossref
Ling Li, Fei Kong, Lei Zhang, Xin Li, Xiaorui Fu, Xinhua Wang, Jingjing Wu, Fangwen Zhang, Liangliang Ren & Mingzhi Zhang. (2020) Apatinib, a novel VEGFR-2 tyrosine kinase inhibitor, for relapsed and refractory nasopharyngeal carcinoma: data from an open-label, single-arm, exploratory study. Investigational New Drugs 38:6, pages 1847-1853.
Crossref
Crossref
Xiangyu Li, Liying Wang, Li Wang, Jiaming Yu, Guohao Lu, Wei Zhao, Congxiu Miao, Changye Zou & Jun Wu. (2020)
Overcoming therapeutic failure in osteosarcoma
via
Apatinib-encapsulated hydrophobic poly(ester amide) nanoparticles
. Biomaterials Science 8:21, pages 5888-5899.
Crossref
Crossref
Li Yanwei, He Feng, Peng Ren, Jie Yue, Wencheng Zhang, Peng Tang, Xiaobin Shang, Qingsong Pang, Dongying Liu, Chuangui Chen, Zhanyu Pan & Yu Zhen Tao. (2020) Safety and Efficacy of Apatinib Monotherapy for Unresectable, Metastatic Esophageal Cancer: A Single-Arm, Open-Label, Phase II Study. The Oncologist 25:10, pages e1464-e1472.
Crossref
Crossref
Jose J. G. Marin, Laura Perez-Silva, Rocio I. R. Macias, Maitane Asensio, Ana Peleteiro-Vigil, Anabel Sanchez-Martin, Candela Cives-Losada, Paula Sanchon-Sanchez, Beatriz Sanchez De Blas, Elisa Herraez, Oscar Briz & Elisa Lozano. (2020) Molecular Bases of Mechanisms Accounting for Drug Resistance in Gastric Adenocarcinoma. Cancers 12:8, pages 2116.
Crossref
Crossref
Qiao Wang, Hongling Peng, Xiaorong Qi, Min Wu & Xia Zhao. (2020) Targeted therapies in gynecological cancers: a comprehensive review of clinical evidence. Signal Transduction and Targeted Therapy 5:1.
Crossref
Crossref
Zhen Yan, Yuan‑Yuan Gu, Xiao‑Di Hu, Qun Zhao, Hai‑Li Kang, Miao Wang, Wei Duan & Yin Guan. (2020) Clinical outcomes and safety of apatinib monotherapy in the treatment of patients with advanced epithelial ovarian carcinoma who progressed after standard regimens and the analysis of the VEGFR2 polymorphism. Oncology Letters 20:3, pages 3035-3045.
Crossref
Crossref
Ning Li, Ziyi Wang, Guangwen Yuan, Yangchun Sun, Rong Zhang, Xiaoguang Li, Nan Li, Jing Wang & Lingying Wu. (2020) An Oral Small Molecule VEGFR2 Inhibitor, Apatinib, in Patients with Recurrent or Refractory Cervical Cancer: A Real World Study. Journal of Oncology 2020, pages 1-6.
Crossref
Crossref
Jia-Yong Liu, Bao-Rang Zhu, Yu-Dong Wang & Xin Sun. (2020) The efficacy and safety of Apatinib mesylate in the treatment of metastatic osteosarcoma patients who progressed after standard therapy and the VEGFR2 gene polymorphism analysis. International Journal of Clinical Oncology 25:6, pages 1195-1205.
Crossref
Crossref
Xiaodan Sun, Ji Li, Yizhuo Li, Shouhan Wang & Qingchang Li. (2020) Apatinib, a Novel Tyrosine Kinase Inhibitor, Promotes ROS-Dependent Apoptosis and Autophagy via the Nrf2/HO-1 Pathway in Ovarian Cancer Cells. Oxidative Medicine and Cellular Longevity 2020, pages 1-19.
Crossref
Crossref
Jun-Hui Guo, Yuan-Yuan Wang, Jiang-Wei Zhang, Pei-Min Liu, Yan-Jun Hao & Hai-Rui Duan. (2020) Clinical effects of apatinib mesylate for treatment of multiple brain micrometastases: Two case reports. World Journal of Clinical Cases 8:7, pages 1326-1336.
Crossref
Crossref
Xiang Wang, Ruixing Zhang, Nan Du, Mudan Yang, Aimin Zang, Likun Liu, Junyan Yu, Jinghua Gao, Junping Zhang, Zhanzhao Fu, Yuchuan Ren, Liwen Ma, Jun Guo, Qingshan Li, Xiaomei Li, Zaiwen Fan, Xiang Song, Zheng Liu, Yan Zhang, Guozhong Li, Zhonghe Yu, Jianfeng Diao, Junmei Jia, Feng Liang, Huaqing Wang, Junzhong Sun, Yunge Gao, Ping Yang, Chunmei Bai, Xiubao Ren & Diansheng Zhong. (2020) An open label, multicenter, noninterventional study of apatinib in advanced gastric cancer patients (AHEAD-G202). Therapeutic Advances in Medical Oncology 12, pages 175883592090542.
Crossref
Crossref
Nazila Fathi Maroufi, Mohammad Reza Rashidi, Vahid Vahedian, Maryam Akbarzadeh, Amir Fattahi & Mohammad Nouri. (2020) Therapeutic potentials of Apatinib in cancer treatment: Possible mechanisms and clinical relevance. Life Sciences 241, pages 117106.
Crossref
Crossref
Jieshan Guan, Zhijie Luo, Zhiwei Xiao, Yubin Xie & Lizhu Lin. (2019) Treatment of consistent BRAF/HRAS gene mutation and MYC amplification radiation-induced abdominal wall angiosarcoma with low-dose apatinib: a case report. BMC Cancer 19:1.
Crossref
Crossref
Yongqiang Zhao, Feifei Liu, Guojing He, Ke Li, Changcheng Zhu, Wei Yu, Conghai Zhang, Mingjin Xie, Jun Lin, Jihong Zhang & Yi Jin. (2019) Discovery of arylamide-5-anilinoquinazoline-8-nitro derivatives as VEGFR-2 kinase inhibitors: Synthesis, in vitro biological evaluation and molecular docking. Bioorganic & Medicinal Chemistry Letters 29:23, pages 126711.
Crossref
Crossref
Hyeon Jeong Yoon, Je Moon Woo, Yong Sok Ji & Kyung Chul Yoon. (2019) Comparison of the Therapeutic Efficacies of Topical Rivoceranib and Topical Bevacizumab in a Murine Model of Corneal Neovascularization. Medicina 55:11, pages 729.
Crossref
Crossref
Ping Fang, Liqin Zhang, Xianru Zhang, Jiawen Yu, Jun Sun, Qi-an Jiang, Mingbao Zha, Anastasia P. Nesterova & Hongbao Cao. (2019) Apatinib Mesylate in the treatment of advanced progressed lung adenocarcinoma patients with EGFR-TKI resistance —A Multicenter Randomized Trial. Scientific Reports 9:1.
Crossref
Crossref
Yao Weitao, Wu Fangxing, Cai Qiqing & Wang Jiaqiang. (2019) Efficacy and safety of apatinib in advanced sarcoma. Anti-Cancer Drugs 30:7, pages 749-756.
Crossref
Crossref